Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566555 | 1.00 | RAF1 (0.38) | RAF1MAPK1KMT2AMAPTGAA | |
| SCHEMBL24312228 | 0.82 | RAF1 (0.43) | RAF1MAPK1MAPTGAASMN1; SMN2 | |
| SCHEMBL24312157 | 0.81 | MAPK1 (0.38) | RAF1MAPK1MAPTGAASMN1; SMN2 | |
| SCHEMBL29566497 | 0.81 | MAPK1 (0.38) | RAF1MAPK1MAPTGAASMN1; SMN2 | |
| SCHEMBL30378747 | 0.79 | MAPK1 (0.41) | RAF1MAPK1KMT2AMAPTGAA | |
| SCHEMBL26090535 | 0.79 | MAPK1 (0.41) | RAF1MAPK1KMT2AMAPTGAA | |
| SCHEMBL24312320 | 0.79 | MAPK1 (0.37) | RAF1MAPK1MAPTGAASMN1; SMN2 | |
| SCHEMBL24312146 | 0.77 | RAF1 (0.38) | RAF1MAPK1MAPTGAASMN1; SMN2 | |
| SCHEMBL24312591 | 0.77 | RAF1 (0.38) | RAF1MAPK1MAPTGAASMN1; SMN2 | |
| SCHEMBL24312573 | 0.77 | MAP3K14 (0.41) | RAF1MAPK1MAPTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023070053-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | RAF1 2/4885MAPK1 268/4885KMT2A 1631/4885 |
| US-11746095-B2 | Inhibtors of RAF kinases | RAF1, BRAF, ARAF | RAF1 1/4885MAPK1 673/4885KMT2A 2824/4885 |
| US-11377431-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | RAF1 2/4885MAPK1 268/4885KMT2A 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.